Advertisement


Matthew R. Zibelman, MD, on Renal Cell Carcinoma: New Results on Combination of Nivolumab and Axitinib

2022 ASCO Genitourinary Cancers Symposium

Advertisement

Matthew R. Zibelman, MD, of Fox Chase Cancer Center, discusses phase I/II results from a study of treatment-naive patients with advanced renal cell carcinoma who received a combination of the immunotherapy (IO) nivolumab and the tyrosine kinase inhibitor (TKI) axitinib. The findings suggest that the efficacy of this regimen is comparable to that of currently available IO/TKI combinations for this population and has a similar safety profile (Abstract 291).



Related Videos

Solid Tumors
Immunotherapy

Hielke-Martijn de Vries, MD, on Penile Cancer: New Data on Atezolizumab and Radiotherapy

Hielke-Martijn de Vries, MD, of the Netherlands Cancer Institute, discusses phase II findings on the use of atezolizumab with or without radiotherapy for patients with advanced squamous cell carcinoma of the penis. The study was designed to address the poor prognosis for this disease by exploring whether a protracted schedule of radiotherapy for locoregional disease, in combination with immunotherapy, could improve outcomes (Abstract 3).

Prostate Cancer

Fred Saad, MD, on Prostate Cancer: Results From the PROpel Trial on Olaparib and Abiraterone

Fred Saad, MD, of the University of Montreal Health Centre, discusses phase III findings demonstrating for the first time the clinical benefits of olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer, irrespective of their homologous recombination repair mutation status. This regimen led to significantly longer radiographic progression-free survival than placebo plus abiraterone (Abstract 11).

Prostate Cancer

Axel S. Merseburger, MD, on Prostate Cancer: New Data From the PRESIDE Trial on Enzalutamide, Docetaxel, and Prednisolone

Axel S. Merseburger, MD, of the University Hospital Schleswig-Holstein, discusses results from a phase IIIb study of chemotherapy-naive patients with metastatic castration-resistant prostate cancer who have been treated with docetaxel plus prednisolone and experienced disease progression on enzalutamide. The data suggest that continued enzalutamide plus docetaxel improved progression-free survival compared with placebo plus docetaxel (Abstract 15).

Kidney Cancer
Bladder Cancer
Prostate Cancer
Genomics/Genetics
Immunotherapy
COVID-19

Sumanta K. Pal, MD, on Advances in Genitourinary Cancer Treatment: Expert Perspective

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses some key research developments in kidney cancer, including data on nivolumab and ipilimumab with or without CBM588 in metastatic renal cell carcinoma; intestinal microbiome associated with the development of grade 3 or 4 adverse events in patients with metastatic disease who have been treated with nivolumab plus ipilimumab and probiotic support; the link between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer; mutations in the androgen receptor gene in patients with prostate cancer receiving novel androgen deprivation treatments; and findings on waning antibody titers in patients who have received COVID-19 vaccinations (Roundup of Abstracts 371, 561, 374, Posters 38 and 48).

Issues in Oncology
Bladder Cancer
Kidney Cancer
Prostate Cancer

Karen E. Knudsen, PhD, MBA, on Addressing Disparities in Genitourinary Cancers

Karen E. Knudsen, PhD, MBA, Chief Executive Officer of the American Cancer Society, discusses ways to address the inequities in genitourinary screening, treatment, and outcomes. Her suggestions focus on increasing awareness of screening, identifying risk factors, the dramatic rise in incidence among Hispanic individuals, and the basis for increased mortality in Black men.

Advertisement

Advertisement




Advertisement